[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Schistosomiasis Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

October 2019 | 40 pages | ID: SD0AADC935DBEN
VPAResearch

US$ 1,699.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Schistosomiasis Drug pipeline report- 2020 is an annual R&D review of Schistosomiasis pipeline candidates. The report presents the current status of all major Schistosomiasis therapeutic compounds. Detailed insights into Schistosomiasis pipeline development, current status, companies, drug profiles and Schistosomiasis preclinical and clinical trials are included.

2020 Schistosomiasis Pipeline Market Insights
Schistosomiasis disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Schistosomiasis therapies, pipeline by phase and others are included.

Schistosomiasis pipeline Drug profiles-
Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Schistosomiasis Therapeutic Drug candidates
Both active and inactive Schistosomiasis pipeline drug candidates are included in the report

Schistosomiasis Clinical Trials and preclinical Studies
Schistosomiasis In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.

Schistosomiasis pipeline market developments
Schistosomiasis Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Schistosomiasis pipeline companies in active development
The report analyzes Schistosomiasis pipeline of the below companies-

Ebelle Pharmaceuticals Inc, Kancera AB, Knight Therapeutics Inc, Merck KGaA, Orygen Biotecnologia SA, Pai Life Sciences Inc, Salvensis, Tongli Biomedical Co Ltd

Report Coverage

What to look out for in 2020
Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

Pipeline Snapshot
Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

Companies
8 Companies investing in Schistosomiasis pipeline from discovery stage to pre-registration phase are included

Drug profiles
Over 10 details of each Schistosomiasis pipeline candidate are included

Company Profiles
Business overview and contact details of all companies operating in the industry are provided

Market Developments
News, Developments and other recent industry developments are included
1. SCHISTOSOMIASIS PIPELINE MARKET INSIGHTS, 2020

1.1 Schistosomiasis Disease Overview
1.2 Schistosomiasis Drug Pipeline Snapshot, 2020
  1.2.1 Schistosomiasis Pipeline Drugs by Phase
  1.2.2 Schistosomiasis Pipeline Drugs by Company
  1.2.3 Schistosomiasis Pipeline Drugs by Mechanism of Action
  1.2.4 Schistosomiasis Pipeline Drugs by Route of Administration

2. SCHISTOSOMIASIS COMPANY WISE PIPELINE DETAILS

Ebelle Pharmaceuticals Inc Schistosomiasis Pipeline Drugs
  Company Profile
  Drug Candidate Details
Kancera AB Schistosomiasis Pipeline Drugs
  Company Profile
  Drug Candidate Details
Knight Therapeutics Inc Schistosomiasis Pipeline Drugs
  Company Profile
  Drug Candidate Details
Merck KGaA Schistosomiasis Pipeline Drugs
  Company Profile
  Drug Candidate Details
Orygen Biotecnologia SA Schistosomiasis Pipeline Drugs
  Company Profile
  Drug Candidate Details
Pai Life Sciences Inc Schistosomiasis Pipeline Drugs
  Company Profile
  Drug Candidate Details
Salvensis Schistosomiasis Pipeline Drugs
  Company Profile
  Drug Candidate Details
Tongli Biomedical Co Ltd Schistosomiasis Pipeline Drugs
  Company Profile
  Drug Candidate Details

3. SCHISTOSOMIASIS DRUG PIPELINE PROFILES

3.1 Discovery and Preclinical Drug Profiles
3.2 Phase 1 Drug Profiles
3.3 Phase 2 Drug Profiles
3.4 Phase 3 Drug Profiles

4. SCHISTOSOMIASIS PIPELINE NEWS AND DEVELOPMENTS

5. APPENDIX

5.1 Primary and Secondary Research Methodology
5.2 Publisher Expertize
5.3 Contacts


More Publications